{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:37:20Z","timestamp":1793648240634,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.rpth.2025.102926","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:09:10Z","timestamp":1750169350000},"page":"102926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice"],"prefix":"10.1016","volume":"9","author":[{"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escuriola Ettingshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye\u2013Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Lelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102926_bib1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/hae.14638","article-title":"Management of haemophilia A with inhibitors: a regional cross-talk","volume":"28","author":"Peyvandi","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib2","first-page":"1","volume":"26","author":"Srivastava","year":"2020"},{"key":"10.1016\/j.rpth.2025.102926_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102434","article-title":"Exploring nonreplacement therapies\u2019 impact on hemophilia and other rare bleeding disorders","volume":"8","author":"Peyvandi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib14","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/s-0043-1777766","article-title":"Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia A with factor VIII inhibitors","volume":"8","author":"Castaman","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2025.102926_bib15","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1182\/bloodadvances.2022007458","article-title":"Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies","volume":"6","author":"Kruse\u2013Jarres","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102926_bib16","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102926_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102926_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12782","article-title":"Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3","volume":"6","author":"Callaghan","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102926_bib21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib23","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.102926_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12837","article-title":"Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY)","volume":"6","author":"Jimenez\u2013Yuste","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtha.2023.01.010","article-title":"Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021","volume":"21","author":"Abbattista","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib28","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jtha.2024.02.009","article-title":"Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data","volume":"22","author":"Cho","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hae.14684","article-title":"Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab","volume":"29","author":"Kizilocak","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2018.08.003","article-title":"Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient\u2019s joint status","volume":"33","author":"Di Minno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.102926_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.832","article-title":"Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: a single-center experience in Bangladesh","volume":"5","author":"Tory","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.rpth.2025.102926_bib35","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/hae.14880","article-title":"Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: a nationwide observational study in Taiwan","volume":"29","author":"Shen","year":"2023","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2025.102926_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2021-147195","article-title":"Emicizumab outcomes in hemophilia A using real-world data from the Canadian Hemophilia Bleeding Disorder Registry","volume":"138","author":"Poon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/hae.14762","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors: three years follow-up from the UK Haemophilia Centre Doctors Organisation (UKHCDO)","volume":"29","author":"Wall","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hae.13877","article-title":"Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors","volume":"26","author":"Ebbert","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib41","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.3390\/jcm10194303","article-title":"Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab","volume":"10","author":"Levy-Mendelovich","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2025.102926_bib42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood-2019-126659","article-title":"Severe bleeding events in hemophilia patients A receiving emicizumab prophylaxis","volume":"134","author":"Zimowski","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib43","doi-asserted-by":"crossref","first-page":"E285","DOI":"10.1002\/ajh.27039","article-title":"Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: real-world retrospective multi-institutional cohort","volume":"98","author":"Batsuli","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2025.102926_bib44","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2025.102926_bib46","first-page":"98","article-title":"Emicizumab prophylaxis in people with haemophilia A: summary of 10 years of safety data on thromboembolic events and thrombotic microangiopathy","volume":"30","author":"Sarouei","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib47","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0038-1656122","article-title":"Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity","volume":"77","author":"Negrier","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1537-2995.1990.30790385521.x","article-title":"Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group","volume":"30","author":"Hilgartner","year":"1990","journal-title":"Transfusion"},{"key":"10.1016\/j.rpth.2025.102926_bib49","series-title":"FEIBA VH in home treatment\u2014a 3-year prospective experience","author":"Negrier","year":"1998"},{"key":"10.1016\/j.rpth.2025.102926_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2516.2009.02104.x","article-title":"FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations","volume":"16","author":"Perry","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JBM.S219573","article-title":"Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)","volume":"10","author":"Rajpurkar","year":"2019","journal-title":"J Blood Med"},{"key":"10.1016\/j.rpth.2025.102926_bib53","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/bloodadvances.2017011536","article-title":"Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data","volume":"1","author":"Rota","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102926_bib54","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1160\/TH17-05-0365","article-title":"Use of bypassing agents and risk of thromboembolic events in patients with haemophilia and inhibitors","volume":"117","author":"Bykov","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib55","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtha.2023.09.017","article-title":"Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab","volume":"22","author":"Atsou","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"Sidonio","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib59","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102926_bib60","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib61","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MBC.0b013e3283001cdc","article-title":"Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial","volume":"19","author":"Young","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.102926_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12695","article-title":"Impact of novel hemophilia therapies around the world","volume":"6","author":"Ozelo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.rpth.2025.102926_bib64","article-title":"Management of breakthrough bleeding episodes in the phase 3 concizumab studies","volume":"8","author":"Mahlangu","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2025.102926_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2023-181263","article-title":"Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 Basis trial","volume":"142","author":"Matino","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102926_bib69","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jth.15323","article-title":"Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in vitro and ex vivo analyses","volume":"19","author":"Kjalke","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102926_bib70","first-page":"S5","article-title":"Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia","volume":"24","author":"Qian","year":"2018","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792500250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:14:11Z","timestamp":1762629251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792500250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S247503792500250X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102926","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Pharmaceuticals International AG. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102926"}}